⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716245 | 0.90 | — | — | |
| SCHEMBL1031487 | 0.90 | — | — | |
| SCHEMBL1030641 | 0.90 | — | — | |
| SCHEMBL11045780 | 0.69 | — | — | |
| SCHEMBL274608 | 0.69 | — | — | |
| SCHEMBL2372331 | 0.68 | — | — | |
| SCHEMBL8040334 | 0.67 | — | — | |
| SCHEMBL2672536 | 0.67 | — | — | |
| SCHEMBL696561 | 0.63 | NOS3 (0.40) | — | |
| SCHEMBL4932949 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151346-A1 | HETEROARYL FLUOROALKENES AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2024-07-18 | — | — | WO | claimed |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2023-05-11 | — | — | US | claimed |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-15 | — | — | US | claimed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | claimed |
| CN-114126713-A | Substituted benzimidazolone compounds | 百时美施贵宝公司 | 2022-03-01 | — | — | CN | claimed |
| CN-113336760-A | Substituted amide derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-113164418-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3845231-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | claimed |
| CN-112955137-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | claimed |
| CN-102414206-A | Isoxazole-pyridine derivatives | HOFFMANN LA ROCHE | 2012-04-11 | — | — | CN | claimed |
| CN-101808996-A | Nicotinamide derivatives, their preparation and their use in therapeutics | SANOFI AVENTIS | 2010-08-18 | — | — | CN | claimed |
| WO-2010053825-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-14 | — | — | WO | claimed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2109611-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-10-21 | — | — | EP | claimed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | claimed |
| WO-2008095944-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | claimed |
| WO-2008022013-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |